Interferon targeted therapies in systemic lupus erythematosus

Area of Science:

• Immunology
• Rheumatology
• Genetics

Background:

• Type I interferons, produced by plasmacytoid dendritic cells (pDCs), are implicated in systemic lupus erythematosus (SLE) pathogenesis.
• Mutations activating the Type I interferon pathway lead to systemic autoimmunity resembling lupus.
• Elevated interferon-stimulated gene expression in lupus patients' peripheral blood mononuclear cells decreases with immunosuppressive treatment.

Purpose of the Study:

• To review the role of Type I interferons in lupus pathogenesis.
• To discuss current and emerging therapeutic strategies targeting the Type I interferon pathway in lupus.

Main Methods:

• Literature review of studies on Type I interferons, pDCs, and lupus.
• Analysis of therapeutic approaches including monoclonal antibodies, interferon alpha kinoid, and other drugs.
• Examination of preclinical models and novel agents targeting Type I interferon production.

Main Results:

• Type I interferons promote autoantibody formation against nuclear debris in lupus.
• Therapies like sifalimumab, rontalizumab, and interferon alpha kinoid directly target Type I interferon.
• Existing lupus treatments (hydroxychloroquine, bortezomib) and novel agents (dihydroartemisinin, kinase inhibitors) reduce Type I interferon levels.

Conclusions:

• Type I interferons are central to lupus pathogenesis.
• Targeting Type I interferons represents a key therapeutic strategy for lupus.
• Ongoing research explores diverse agents to modulate Type I interferon activity in SLE.